X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs NOVARTIS - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD NOVARTIS MERCK LTD/
NOVARTIS
 
P/E (TTM) x 47.9 322.3 14.9% View Chart
P/BV x 7.2 35.7 20.2% View Chart
Dividend Yield % 0.4 1.3 30.6%  

Financials

 MERCK LTD   NOVARTIS
EQUITY SHARE DATA
    MERCK LTD
Dec-16
NOVARTIS
Mar-18
MERCK LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,060758 139.8%   
Low Rs623579 107.6%   
Sales per share (Unadj.) Rs632.4228.4 276.9%  
Earnings per share (Unadj.) Rs45.731.7 144.0%  
Cash flow per share (Unadj.) Rs62.332.8 190.2%  
Dividends per share (Unadj.) Rs11.0010.00 110.0%  
Dividend yield (eoy) %1.31.5 87.4%  
Book value per share (Unadj.) Rs388.8297.1 130.9%  
Shares outstanding (eoy) m16.6024.69 67.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.9 45.5%   
Avg P/E ratio x18.421.1 87.4%  
P/CF ratio (eoy) x13.520.4 66.2%  
Price / Book Value ratio x2.22.2 96.2%  
Dividend payout %24.131.5 76.4%   
Avg Mkt Cap Rs m13,96916,505 84.6%   
No. of employees `0001.60.7 237.0%   
Total wages/salary Rs m1,4871,445 102.9%   
Avg. sales/employee Rs Th6,631.98,441.3 78.6%   
Avg. wages/employee Rs Th939.22,163.6 43.4%   
Avg. net profit/employee Rs Th479.41,173.1 40.9%   
INCOME DATA
Net Sales Rs m10,4985,639 186.2%  
Other income Rs m2421,718 14.1%   
Total revenues Rs m10,7417,357 146.0%   
Gross profit Rs m1,135-63 -1,816.5%  
Depreciation Rs m27625 1,088.9%   
Interest Rs m055 0.0%   
Profit before tax Rs m1,1021,575 70.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m343792 43.4%   
Profit after tax Rs m759784 96.8%  
Gross profit margin %10.8-1.1 -975.7%  
Effective tax rate %31.150.3 62.0%   
Net profit margin %7.213.9 52.0%  
BALANCE SHEET DATA
Current assets Rs m6,4109,522 67.3%   
Current liabilities Rs m8,8283,296 267.8%   
Net working cap to sales %-23.0110.4 -20.9%  
Current ratio x0.72.9 25.1%  
Inventory Days Days5837 157.5%  
Debtors Days Days3828 135.1%  
Net fixed assets Rs m1,40646 3,057.4%   
Share capital Rs m166123 134.5%   
"Free" reserves Rs m6,2867,213 87.1%   
Net worth Rs m6,4557,336 88.0%   
Long term debt Rs m00-   
Total assets Rs m8,82811,105 79.5%  
Interest coverage xNM29.5-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.5 234.2%   
Return on assets %8.67.6 113.8%  
Return on equity %11.810.7 110.1%  
Return on capital %17.122.2 76.8%  
Exports to sales %8.30-   
Imports to sales %21.00-   
Exports (fob) Rs m869NA-   
Imports (cif) Rs m2,209NA-   
Fx inflow Rs m95961 1,582.2%   
Fx outflow Rs m2,6123,630 72.0%   
Net fx Rs m-1,653-3,570 46.3%   
CASH FLOW
From Operations Rs m1,0701,610 66.5%  
From Investments Rs m-750687 -109.1%  
From Financial Activity Rs m-150-2,677 5.6%  
Net Cashflow Rs m171-380 -45.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 75.0 69.1%  
Indian inst/Mut Fund % 18.2 2.0 910.0%  
FIIs % 1.0 1.6 62.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 21.5 135.3%  
Shareholders   28,591 41,647 68.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  DIVIS LABORATORIES  FULFORD INDIA  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Aug 17, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE MERCK LTD WITH

MARKET STATS